Outcomes of long-term maintenance infliximab therapy in adult patients with moderate to severe Crohn's disease from March 2003 to December 2010: A single centre experience

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11320%2F12%3A10125932" target="_blank" >RIV/00216208:11320/12:10125932 - isvavai.cz</a>

Výsledek na webu

<a href="http://www.remedia.cz/Archiv-rocniku/Rocnik-2012/3-2012/Outcomes-of-long-term-maintenance-infliximab-therapy-in-adult-patients-with-moderate-to-severe-Crohn-s-disease-from-March-2003-to-December-2010/e-1dQ-1gv-1h5.magarticle.aspx" target="_blank" >http://www.remedia.cz/Archiv-rocniku/Rocnik-2012/3-2012/Outcomes-of-long-term-maintenance-infliximab-therapy-in-adult-patients-with-moderate-to-severe-Crohn-s-disease-from-March-2003-to-December-2010/e-1dQ-1gv-1h5.magarticle.aspx</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Outcomes of long-term maintenance infliximab therapy in adult patients with moderate to severe Crohn's disease from March 2003 to December 2010: A single centre experience

Popis výsledku v původním jazyce

We evaluated the long-term clinical benefit of infliximab (IFX) in a total of 74 patients with moderate to severe Crohn's disease (CD); the median follow-up was 16 months (interquartile range 13-35). Methods: We compared the quality of mucosal healing (MH) in 3 groups of patients with CD. Group I (GI): CD duration < 3 years, treated with IFX. Group II (GII): CD duration > 3 years, treated with IFX. Group III (GIII): CD duration > 3 years, treated with IFX + azathioprine (AZA). Results: At week 52, deepclinical remission was observed in seven of 21 patients in GI (33.33%), in three of 19 patients in GII (15.70%), and in eight of 20 patients in GIII (40.00%). The differences among groups were statistically significant in the likelihood ratio test (P = 0.019) and logrank test (P = 0.042). The covariate analysis showed significant differences in the outcomes between GIII and GII (OR 7.20, P = 0.05) and between GI and GII (OR 6.3, P = 0.052), and a nonsignificant difference between GIII an

Název v anglickém jazyce

Outcomes of long-term maintenance infliximab therapy in adult patients with moderate to severe Crohn's disease from March 2003 to December 2010: A single centre experience

Popis výsledku anglicky

We evaluated the long-term clinical benefit of infliximab (IFX) in a total of 74 patients with moderate to severe Crohn's disease (CD); the median follow-up was 16 months (interquartile range 13-35). Methods: We compared the quality of mucosal healing (MH) in 3 groups of patients with CD. Group I (GI): CD duration < 3 years, treated with IFX. Group II (GII): CD duration > 3 years, treated with IFX. Group III (GIII): CD duration > 3 years, treated with IFX + azathioprine (AZA). Results: At week 52, deepclinical remission was observed in seven of 21 patients in GI (33.33%), in three of 19 patients in GII (15.70%), and in eight of 20 patients in GIII (40.00%). The differences among groups were statistically significant in the likelihood ratio test (P = 0.019) and logrank test (P = 0.042). The covariate analysis showed significant differences in the outcomes between GIII and GII (OR 7.20, P = 0.05) and between GI and GII (OR 6.3, P = 0.052), and a nonsignificant difference between GIII an

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FJ - Chirurgie včetně transplantologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2012

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Remedia

ISSN

0862-8947

e-ISSN

—

Svazek periodika

22

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

5

Strana od-do

235-240

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—